Roche’s Tecentriq With Lurbinectedin Increases Survival From Small-Cell Lung Cancer, Study Says Late-stage trials showed the combination led to a 27% reduction in the risk of death, the company said ...

Tecentriq may be used with the chemotherapy medicines carboplatin and etoposide as their first treatment when their lung cancer: is a type called “extensive-stage small cell lung cancer ...

Genentech has an extensive development program for Tecentriq, alone and in combination, including multiple ongoing and planned Phase 3 studies across different lung, genitourinary, skin, breast ...

Tecentriq is available as a liquid solution that’s given as an IV infusion (an injection into your vein over a period of time). You’ll receive infusions at your doctor’s office or a clinic.

Patients assigned Tecentriq had a median overall survival of 10.3 months compared with 9.2 months in those assigned chemotherapy. The two-year survival rate for the Tecentriq group was 24% versus 12% ...

Tecentriq is approved in the US, EU and countries around the world, either alone or in combination with targeted therapies and/or chemotherapies in various forms of NSCLC, SCLC, certain types of ...

Tecentriq can cause serious side effects, including: Lung problems (pneumonitis) –signs and symptoms of pneumonitis may include new or worsening cough, shortness of breath, and chest pain ...

“Tecentriq is now the first and only cancer immunotherapy available for adjuvant treatment of NSCLC, introducing a new era where people diagnosed with early lung cancer may have the opportunity ...

Tecentriq cut the risk of disease recurrence or death by 21%, the data showed. For a smaller group of patients whose tumours expressed PD-L1, a protein that helps the cancer hide from the immune ...

In 2019, the FDA granted accelerated approval to Tecentriq, a PD-L1 blocking antibody, plus Abraxane for unresectable locally advanced or metastatic TNBC based on progression free survival results ...

Roche has voluntarily withdrawn the U.S. indication of Tecentriq for treating a form of bladder cancer following consultation with the Food and Drug Administration (FDA), the Swiss drugmaker said ...